Concordant overexpression of phosphorylated ATF2 and STAT3 in extramammary Paget's disease

Journal of Cutaneous Pathology

Volumn 36, Issue 4, 2009, Pages 402-408

  Chen, Si Yuan ^a,b   Takeuchi, Satoshi ^a   Moroi, Yoichi ^a   Hayashida, Sayaka ^a   Kido, Makiko ^a   Tomoeda, Hiroto ^a   Uenotsuchi, Takeshi ^a   Tu, Ya Ting ^b   Furue, Masutaka ^a   Urabe, Kazunori ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; APOPTOSIS SIGNAL REGULATING KINASE 1; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MIXED LINEAGE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PAGET SKIN DISEASE; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ACTIVATING TRANSCRIPTION FACTOR 2; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PAGET DISEASE, EXTRAMAMMARY; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 61449233249     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2008.01076.x     Document Type: Article

References (37)

1. Lloyd J, Flanagan AM. Mammary and extramammary Paget's disease. J Clin Pathol 2000 53 : 742.
2. Ohnishi T, Watanabe S. The use of cytokeratins 7 and 20 in the diagnosis of primary and secondary extramammary Paget's disease. Br J Dermatol 2000 142 : 243.
3. Liu F, Green MR. A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1a protein. Cell 1990 61 : 1217.
4. Falvo JV, Parekh BS, Lin CH, et al. Assembly of a functional beta interferon enhanceosome is dependent on ATF-2-c-jun heterodimer orientation. Mol Cell Biol 2000 20 : 4814.
5. Tsai EY, Jain J, Pesavento PA, et al. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol Cell Biol 1996 16 : 459.
6. Shimizu M, Nomura Y, Suzuki H, et al. Activation of the rat cyclin A promoter by ATF2 and Jun family members and its suppression by ATF4. Exp Cell Res 1998 239 : 93.
7. Bhoumik A, Huang TG, Ivanov V, et al. An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest 2002 110 : 643.
8. Bhoumik A, Gangi L, Ronai Z. Inhibition of melanoma growth and metastasis by ATF2-derived peptides. Cancer Res 2004 64 : 8222.
9. Morton S, Davis RJ, Cohen P. Signalling pathways involved in multisite phosphorylation of the transcription factor ATF-2. FEBS Lett 2004 572 : 177.
10. Ouwens DM, de Ruiter ND, van der Zon GC, et al. Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-p38. EMBO J 2002 21 : 3782.
11. Lewis JS, Vijayanathan V, Thomas TJ, et al. Activation of cyclin D1 by estradiol and spermine in MCF-7 breast cancer cells: a mechanism involving the p38 MAP kinase and phosphorylation of ATF-2. Oncol Res 2005 15 : 113.
12. Recio JA, Merlino G. Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1. Cancer Res 2003 63 : 1576.
13. Papassava P, Gorgoulis VG, Papaevangeliou D, et al. Overexpression of activating transcription factor-2 is required for tumor growth and progression in mouse skin tumors. Cancer Res 2004 64 : 8573.
14. Horvath CM. STAT proteins and transcriptional responses to extracellular signals. TIBS 2000 25 : 496.
15. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 1997 88 : 435.
16. Garcia R, Yu CL, Hudnall A, et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 1997 8 : 1267.
17. Niu G, Bowman T, Huang M, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002 21 : 7001.
18. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999 10 : 105.
19. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000 19 : 2489.
20. Fernandes A, Hamburger AW, Gerwin BI. ErbB-2 kinase is required for constitutive Stat3 activation in malignant human lung epithelial cells. Int J Cancer 1999 83 : 564.
21. Ni Z, Lou W, Leman ES, et al. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 2000 60 : 1225.
22. Burke WM, Jin X, Lin HJ, et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001 20 : 7925.
23. Liu HJ, Moroi Y, Masuda T, et al. Expression of phosphorylated Stat3, cyclin D1 and Bcl-xL in extramammary Paget disease. Br J Dermatol 2006 154 : 926.
24. Chen SY, Takeuchi S, Urabe K, et al. Overexpression of phosphorylated-ATF2 and STAT3 in cutaneous angiosarcoma and pyogenic granuloma. J Cutan Pathol 2007. doi: 10.1111/j.1600-0560.2007.00887.x.
25. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002 2 : 740.
26. Steinmuller L, Cibelli G, Moll JR, et al. Regulation and composition of activator protein 1 (AP-1) transcription factors controlling collagenase and c-Jun promoter activities. Biochem J 2001 360 : 599.
27. Ma XT, Wang S, Ye YJ, et al. Relationship of Stat3 and its target gene products with malignancy in human colorectal carcinoma. Ai Zheng 2003 22 : 1135.
28. Masuda M, Suzui M, Yasumatu R, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002 62 : 3351.
29. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003 3 : 721.
30. Li WD, Liu TS, Yao QJ, et al. Correlation between the activation of AP-1 signal transduction pathway and metastasis of colorectal carcinoma. Zhonghua Wei Chang Wai Ke Za Zhi 2005 4 : 356.
31. Gum R, Wang H, Lengyel E, et al. Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene 1997 14 : 1481.
32. Lee SO, Jeong YJ, Im HG, et al. Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. Biochem Biophys Res Commun 2007 354 : 165.
33. Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003 22 : 3152.
34. Pusztai L, Clover LM, Cooper K, et al. Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast. Br J Cancer 1994 70 : 289.
35. Carrel S, Hartmann F, Salvi S, et al. Expression of type A and B tumor necrosis factor (TNF) receptors on melanoma cells can be regulated by dbc-AMP and IFN gamma. Int J Cancer 1995 62 : 76.
36. Liu ZG. Molecular mechanism of TNF signaling and beyond. Cell Res 2005 15 : 24.
37. Trauzold A, Roder C, Sipos B, et al. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J 2005 19 : 620.